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Abstract
Background: Anti-cancer drugs access solid tumors via blood vessels, and must penetrate tumor
tissue to reach all cancer cells. Previous studies have demonstrated steep gradients of decreasing
doxorubicin fluorescence with increasing distance from blood vessels, such that many tumor cells
are not exposed to drug. Studies using multilayered cell cultures show that increased P-
glycoprotein (PgP) is associated with better penetration of doxorubicin, while PgP inhibitors
decrease drug penetration in tumor tissue. Here we evaluate the effect of PgP expression on
doxorubicin distribution in vivo.
Methods: Mice bearing tumor sublines with either high or low expression of PgP were treated
with doxorubicin, with or without pre-treatment with the PgP inhibitors verapamil or PSC 833. The
distribution of doxorubicin in relation to tumor blood vessels was quantified using
immunofluorescence.
Results: Our results indicate greater uptake of doxorubicin by cells near blood vessels in wild type
as compared to PgP-overexpressing tumors, and pre-treatment with verapamil or PSC 833
increased uptake in PgP-overexpressing tumors. However, there were steeper gradients of
decreasing doxorubicin fluorescence in wild-type tumors compared to PgP overexpressing tumors,
and treatment of PgP overexpressing tumors with PgP inhibitors led to steeper gradients and
greater heterogeneity in the distribution of doxorubicin.
Conclusion: PgP inhibitors increase uptake of doxorubicin in cells close to blood vessels, have
little effect on drug uptake into cells at intermediate distances, and might have a paradoxical effect
to decrease doxorubicin uptake into distal cells. This effect probably contributes to the limited
success of PgP inhibitors in clinical trials.
Background
Effective systemic treatment of solid tumors requires that
constituent cells be sensitive to the drug(s) used and that
the drug(s) be able to achieve a concentration within the
cells sufficient to cause cytotoxicity. The ability of anti-
cancer drugs to gain access to all of the viable cells in solid
tumors depends on efficient delivery of drugs through the
vascular system, and on penetration of drugs to tumor
cells that are distant from blood vessels. Solid tumors
have an inefficient bloody supply with tortuous and leaky
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vessels, large intercapillary distances and intermittent
blood flow. There is evidence that several anticancer drugs
have poor penetration of tumor tissue from blood vessels
[1-5]. In particular there are steep gradients of decreasing
doxorubicin fluorescence with increasing distance from
blood vessels in tumors grown in mice and in human
breast cancer, suggesting that limited drug penetration
may be an important cause of resistance to treatment
[6,7].
Many of the anticancer drugs in clinical use are natural
products, or derivatives of natural products (e.g. anthracy-
clines such as doxorubicin, vinca alkaloids such as vincris-
tine and taxanes) and they share common mechanisms of
resistance. Many of these drugs are high affinity substrates
for energy-dependent membrane transporter proteins that
act to pump drugs out of cells. The best characterized of
these drug efflux pumps is P-glycoprotein (PgP) [8-10]. P-
glycoprotein is widely expressed in many human cancers
including those of the liver, pancreas, kidney, ovary and
breast. PgP is encoded by the multidrug resistance
(MDR1) gene in humans and is a member of a large fam-
ily of ATP-dependent transporters known as the ATP-
binding cassette (ABC) family. Levels of PgP correlate with
drug resistance in several different cancers [11,12]. This
has led to the development of agents that reverse resist-
ance to PgP substrates by inhibiting the action of the
pump. However, while phase II studies have suggested
that PgP inhibitors might increase drug sensitivity [13,14],
the majority of randomized controlled trials evaluating
PgP substrate drugs used in combination with or without
PgP modulators, have not shown significant improve-
ments in outcome [15]. Various factors have been attrib-
uted to the failure of PgP modulators in clinical trials such
as high levels of toxicity and pharmacokinetic interactions
with the anticancer drugs [15,16]. In the last decade novel
techniques using liposome-encapsulated doxorubicin in
combination with PgP inhibitors such as verapamil and
PSC 833 have been developed to increase intracellular
drug concentration and minimize toxicity [17-19], how-
ever clinical data showing significant improvements in
outcome have yet to be reported. Thus, other factors may
also contribute in explaining the limited effectiveness of
PgP inhibitors in vivo.
Studies have revealed differences in drug distribution
within  ex vivo tumor tissue models containing cells
expressing low levels of PgP and those with high PgP
expression, and these distributions can be modified by
PgP inhibitors [20,21]. The role of PgP and its inhibitors
to affect drug distribution within the microenvironment
of solid tumors has not been studied. In tumors that
express low levels of PgP, it has been demonstrated that
large quantities of drug remain in the cell layers closest to
blood vessels, while distal cells acquire little to no drug
[7,22]. We hypothesized that PgP, by preventing cellular
accumulation of drug in cells close to blood vessels would
allow greater quantities of drug to be available to distal
cells. Studies of drug penetration through multilayered
cell cultures (MCC) support this hypothesis [20].
Although cellular accumulation of drug is important for
cytotoxicity, if it is localized to perivascular regions, then
there is likely to be a limited overall therapeutic effect on
the tumor. Here we examine in solid tumor models the
trade-off between drug uptake and drug distribution that
is presented by PgP overexpression and PgP inhibitors.
Methods
Drugs and reagents
Doxorubicin (Pharmacia, Mississauga, Canada) was pur-
chased from the hospital pharmacy as a solution at a con-
centration of 2 mg/mL. Purified rat anti-mouse CD31
(platelet/endothelial adhesion molecule 1) monoclonal
antibody was purchased from BD PharmMingen (Missis-
sauga, Canada), and Cy3-conjugated goat anti-rat IgG sec-
ondary antibody was purchased from Jackson
ImmunoResearch Laboratories, Inc. (Pennsylvania, USA).
The first-generation PgP inhibitor, verapamil was pur-
chased from Sigma Laboratories (Oakville, Canada). The
second-generation inhibitor, PSC 833 or valspodar, was
generously provided by Novartis (Basel, Switzerland).
Tumor models
The mouse mammary sarcoma EMT6, and its PgP-upreg-
ulated variant AR1, were provided originally by Dr Peter
Twentyman, Cambridge UK. The human breast cancer cell
line MCF-7 was obtained from the American Type Culture
Collection (ATCC; Virginia, USA), and its PgP upregulated
variants BC19 and MCF-ADR were provided by Dr. Mari-
lyn Morris (Buffalo, NY), and Dr. Kenneth Cowan
(Nebraska).
EMT6 and MCF-7 cells were maintained as monolayers in
α-MEM and RPMI media respectively, supplemented with
10% FCS at 37°C in a humidified atmosphere of 95% air
plus 5% CO2. The AR1, BC19 and MCF-7/ADR cell lines
were maintained in similar conditions to the parental
lines with the exception that the media contained 10 μg/
mL doxorubicin.
Tumors were generated by subcutaneous injection of 1 - 5
× 106 exponentially growing cells into the left and right
flank regions of 6-8 week old Balb/C (EMT6 and AR1) or
athymic nude (MCF-7, BC19 and MCF-7/ADR) female
mice. Mice were housed five per cage in our animal col-
ony. Sterile water and food were given ad libitum. All pro-
cedures were carried out following approval of the
Institutional Animal Care Committee.
Evaluation of Doxorubicin Distribution
Tumor-bearing mice were divided randomly into groups
of five and were treated when the mean tumor diameterBMC Cancer 2009, 9:356 http://www.biomedcentral.com/1471-2407/9/356
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was in the range of 8-12 mm. Animals were treated with
doxorubicin, doxorubicin and a PgP inhibitor, or phos-
phate-buffered saline (CaCl2-MgCl2). Doxorubicin was
given intravenously at a dose of 25 mg/kg to facilitate
detection and quantification of drug auto-fluorescence.
Each PgP inhibitor was administered intraperitoneally
two hours prior to doxorubicin treatment at a dose of 25
mg/kg. Animals were killed 10 minutes after doxorubicin
injection and the tumors were excised. The tissues were
embedded immediately in OCT compound, frozen in liq-
uid nitrogen, and stored at -70°C prior to tissue section-
ing and immunohistochemical staining. Cryostat sections
10 μm thick were cut at 3 levels approximately 100 μm
apart from each tumor, mounted on glass slides and
allowed to air dry.
Fluorescence Imaging
Doxorubicin auto-fluorescence was detected utilizing an
Olympus Upright BX50 microscope with a 100 W HBO
mercury light source equipped with 530 to 560 nm excita-
tion and 573 to 647 nm emission filter sets. Tissue sec-
tions were imaged with a Photometrics CoolSNAP HQ2
(monochrome for fluorescence imaging) camera and tiled
using a motorized stage so that the distribution of doxo-
rubicin was obtained for the entire tissue section. All
images were captured in 8-bit signal depth and subse-
quently pseudo-colored.
Blood vessels in tissue sections were recognized by the
expression of CD31 on endothelial cells. Subsequent to
imaging of doxorubicin, tissue sections were stained with
a rat anti-CD31 antibody (1/100) followed by a Cy3-con-
jugated goat anti-rat IgG secondary antibody (1/400). Tis-
sue sections were re-imaged in an identical way to that
used to capture doxorubicin fluorescence.
Image analysis
Composite images of doxorubicin and CD31 were gener-
ated utilizing Media Cybernetics Image Pro PLUS software
(version 5.0). Images displaying anti-CD31 staining were
converted to a black and white binary image, and small
white objects were removed as artifacts based on conserv-
ative estimation of minimal capillary diameter [23]. The
resultant image was overlaid with the corresponding field
of view displaying doxorubicin fluorescence resulting in
an 8 bit black and white image with blood vessels identi-
fied by pixels with intensities between 250-255 (white)
and doxorubicin ranging from 0-249. Several regions, 1.6
mm2 in area, with moderate blood vessel density were
selected from each tissue section. Blood vessel density was
determined by quantifying the number of pixels with
intensities between 250-255 as a percent of the number of
pixels with intensities from 1-249 using Image J software.
Areas of necrosis and staining artifact were excluded. To
minimize noise from tissue auto-fluorescence a minimum
signal level just below threshold for detection of doxoru-
bicin was set for each tissue section; this was based on an
average background reading from regions without nuclear
fluorescence/staining. The pixel intensity (the area of each
pixel was 0.4 μm2) and distance to the nearest vessel for
all pixels within the selected region of interest above
threshold were measured with a customized algorithm.
Doxorubicin intensity (I) was averaged over all pixels at a
given distance (x) from the nearest vessel and plotted as a
function of distance to the nearest vessel. Linear regres-
sion was performed to correlate the average doxorubicin
fluorescence intensity with distance from the nearest
blood vessel; the slope of the linear regression was statis-
tically compared between treatment groups using ANOVA
and subsequent t-tests. All linear regressions were statisti-
cally significant and residual plots showed no consistent
patterns.
A model comparing doxorubicin distribution in PgP over-
expressing tumors pre-treated with either saline or a PgP
inhibitor was generated using the mean slope and y-inter-
cept from the linear regressions for both the murine and
xenograft tumor types.
Growth delay studies
Mice bearing EMT6 or AR1 tumors were divided into six
groups of 4-5 mice each and treated with either saline,
doxorubicin alone (8 mg/kg i.v., verapamil alone (25 mg/
kg i.p.), PSC 833 alone (25 mg/kg), verapamil + doxoru-
bicin (25 mg/kg + 8 mg/kg) or PSC 833 + doxorubicin (25
mg/kg + 8 mg/kg). In the latter two groups mice were
treated with the PgP inhibitor 2 hours prior to doxoru-
bicin treatment. Every 2-3 days the length and width of
the tumors were measured using calipers and tumor vol-
ume was calculated. Measurements were taken until
tumors reached their maximum limit in size. The body
weight of the mice was also measured.
Results
Blood vessel density
Blood vessel density within areas of interest was measured
and found to be within a small range. Murine tumors are
significantly more vascular than the xenografts (Table 1).
Within a given tumor section there are small areas with
high blood vessel density where no gradients of decreas-
ing doxorubicin fluorescence are observed, but the major-
ity of the tumor section is composed of areas of moderate
blood vessel density with gradients of decreasing doxoru-
bicin fluorescence with increasing distance from vessels.
PgP overexpression and doxorubicin distribution
Representative composite images showing the distribu-
tion of doxorubicin 10 minutes after administration in
relation to blood vessels of wild-type EMT6 tumors, andBMC Cancer 2009, 9:356 http://www.biomedcentral.com/1471-2407/9/356
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in tumors derived from cells that over-express PgP are
shown in Figures 1A and 1B; similar images for MCF7/
BC19 xenografts are shown in Figures 1C and 1D. A sum-
mary of data obtained from these sections is provided in
Table 1. In PgP overexpressing tumors, a more homogene-
ous distribution of doxorubicin is observed as compared
to wild-type tumors of both murine and human origin
(Figure 1). The gradient of decreasing doxorubicin fluo-
rescence intensity is significantly greater in wild-type
tumors that have low levels of PgP expression (Table 1).
Whereas wild-type tumors show an exponential decrease
in doxorubicin fluorescence with distance from blood ves-
sels, PgP overexpressing tumors show a more linear
decrease (Figure 2). Close to blood vessels (i.e. in the first
10  μm), doxorubicin uptake is significantly lower in
tumors that overexpress PgP, but at 50-60 μm from blood
vessels, the difference in doxorubicin uptake is less and by
110-120 μm, there is no significant difference (Table 1
and Figure 2).
PgP inhibitors and doxorubicin penetration
The effects of verapamil and PSC 833 on distribution of
doxorubicin in PgP-overexpressing AR1 tumors are shown
in Figures 3A and 3B, and for corresponding BC19
xenografts in Figures 3C and 3D. Both PgP inhibitors lead
to an increase in uptake of doxorubicin by cells close to
blood vessels, but increase the gradient of decreasing
intensity so that the distribution is more heterogeneous
and similar to that of wild-type tumors (Table 1). Figure 4
shows the distribution of doxorubicin in PgP overexpress-
ing tumors with or without pretreatment with PgP inhib-
itors. Doxorubicin fluorescence intensity in the first 10
μm from blood vessels is significantly greater in PgP over-
expressing tumors that were pretreated with verapamil
and PSC 833 in the murine tumor model, and with PSC
833 in the xenograft model. At further distances (110-120
μm), no significant difference is observed in doxorubicin
uptake between control tumors and tumors pretreated
with PgP inhibitors (Table 1 and Figure 4).
At distances greater than about 90 - 100 μm from blood
vessels estimates of doxorubicin fluorescence are subject
to noise, most likely due to the influence of closer blood
vessels out of the plane of the sections. While in some
areas of the tumors, neighboring vessels may contribute
doxorubicin fluorescence in distal cells, in other areas this
may not be the case and there may be a sharp decrease in
doxorubicin. We have shown the average doxorubicin dis-
tribution taken from several various areas of interest.
Modeling from this data by removing noise from neigh-
boring vessels suggests that the use of potent PgP inhibi-
tors, such as PSC 833 might lead to a paradoxical decrease
in the uptake of doxorubicin in tumor cells situated more
distant from tumor blood vessels (Figure 4c). According
to the model, at around 90-100 μm in the murine model
and 100-115 μm in the xenograft model doxorubicin flu-
orescence intensity is greater in the PgP overexpressing
tumors that are treated with doxorubicin alone compared
to those pretreated with a PgP inhibitor.
Table 1: Characteristics of wild-type (EMT6, MCF-7) and PgP overexpressing tumors (AR1, BC19) at 10 minutes after treatment with 
doxorubicin (DOX) or with pre-treatment 2 hours earlier with inhibitors of PgP.
Tumor Type PgP vs. 
Wild-type
Treatment Blood Vessel 
Density
DOX uptake at distance from the nearest 
blood vessel
Gradient of 
Decreasing 
DOX Intensity
10-20 μm 50-60 μm 110-120 μm
EMT6 Wild Type DOX 4.7 ± 1.2 29.4 ± 6.1a 15.6 ± 1.9 11.3 ± 2.4 -0.23 ± 0.08c
AR1 Overexpress 
PgP
DOX 6.0 ± 1.4 17.1 ± 2.9ab 10.5 ± 2.8c 7.4 ± 1.6 -0.11 ± 0.03cde
AR1 Overexpress 
PgP
Verapamil + 
DOX
4.4 ± 1.1 24.7 ± 8.3 13.7 ± 4.2 9.2 ± 4.0 -0.18 ± 0.06d
AR1 Overexpress 
PgP
PSC 833 + 
DOX
4.7 ± 1.3 34.0 ± 4.3b 16.4 ± 2.3c 12.1 ± 3.7 -0.27 ± 0.04e
MCF-7 Wild Type DOX 2.6 ± 0.7 23.8 ± 4.2f 13.7 ± 2.5 10.4 ± 2.3 -0.16 ± 0.05h
BC19 Overexpress 
PgP
DOX 2.7 ± 0.4 13.0 ± 4.3fg 9.6 ± 2.8 8.7 ± 3.5 -0.05 ± 0.03hij
BC19 Overexpress 
PgP
Verapamil + 
DOX
3.6 ± 0.8 22.1 ± 5.9 13.9 ± 3.7 9.2 ± 1.1 -0.14 ± 0.04i
BC19 Overexpress 
PgP
PSC 833 + 
DOX
2.9 ± 0.7 24.2 ± 4.1g 14.4 ± 2.5 10.9 ± 3.6 -0.17 ± 0.05j
Top and bottom panels were tested separately for significant differences using ANOVA and subsequent t-tests
Within the top panel, a-e represent the pairs of data that are statistically significant (p < 0.05)
Within the bottom panel, f-j represent the pairs of data that are statistically significant (p < 0.05)   BMC Cancer 2009, 9:356 http://www.biomedcentral.com/1471-2407/9/356
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Growth delay and toxicity
Doxorubicin led to modest delay in growth of wild-type
EMT6 tumors (Figure 5A) but had no significant effect on
PgP overexpressing AR1 tumours. The PgP inhibitors did
not modify growth delay for either type of tumor. Body
weight was used as an indication of toxicity. Most treat-
ments were well tolerated and caused no significant loss
of body weight after treatment. The combination of doxo-
rubicin and PSC 833 was toxic to mice and caused a 20-
25% reduction in body weight within the first 3-5 days
(data not shown). Mice in this group were killed after 5
days because of this toxicity.
Discussion
In order for chemotherapy to have an optimal effect
against solid tumors, there must be adequate distribution
of drugs, such that there is accumulation of drug within all
cancer cell populations that can regenerate the tumor.
Repopulation of surviving tumor cells between courses of
chemotherapy is an important mechanism of drug resist-
ance [24-28], and viable cells distal from blood vessels
that do not receive cytotoxic concentrations of drug might
be an important source of such repopulation [29].
Drug distribution may be influenced in tumor tissue by
the presence of high interstitial fluid pressure, an exten-
sive extracellular matrix, cell-cell contact and the expres-
sion of efflux pumps such as PgP on the cell surface. It has
been proposed that since PgP and other drug transporters
reduce cellular accumulation of their substrates, they
might assist in transporting the drugs to neighboring cells
farther away from blood vessels, resulting in a net increase
in tissue penetration of chemotherapeutic agents [2]. This
hypothesis has been supported by the observation of
increased penetration of [14C] doxorubicin through drug-
resistant MCCs (PgP overexpressing) compared to drug-
sensitive MCCs (wild-type) [20]; inhibitors of PgP stimu-
lated cellular accumulation of drugs, but resulted in
Distribution of doxorubicin in solid tumors Figure 1
Distribution of doxorubicin in solid tumors. Murine 
tumors EMT6 (A) and its PgP overexpressing subline AR1 (B) 
and MCF-7 human breast cancer xenograft (C) and its PgP 
overexpressing subline BC19 (D) were resected from Balb/C 
and nude mice, respectively. Doxorubicin is shown in blue 
and blood vessels are shown in red. Note more uniform dis-
tribution of doxorubicin in the PgP overexpressing tumors. 
(Scale bars = 100 μm)
name 
A B 
C D
Mouse 
Human 
The gradient of doxorubicin fluorescence intensity in relation to distance from the nearest blood vessel Figure 2
The gradient of doxorubicin fluorescence intensity in relation to distance from the nearest blood vessel. Mice-
bearing either EMT6 or AR1 tumors (A) (n = 6 tumors each) or MCF-7 or BC19 xenografts (B) (n = 11 and 5 tumors, respec-
tively) were treated with doxorubicin and their tumors were resected, sectioned and imaged. Image analysis was undertaken 
using customized algorithms. Values represent mean ± standard error.
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reduced penetration through tumor tissue in this model
[20]. While using MCCs provides insight into the penetra-
tion of drugs through solid tissue, they lack the 3-dimen-
sional heterogeneity of solid tumors. In studies done
using multicellular spheroids, verapamil showed limited
reversal of resistance by doxorubicin likely due to its small
diameter (approx. 100 μm) and acidic microenvironmen-
tal affects on verapamil activity [30,31]. When a wide
array of PgP reversal agents including cyclosporin A, vera-
pamil, quinidine, and sodium orthovanadate were used
in larger spheroids an increase in doxorubicin fluores-
cence as far as 80 μm was observed. However, doxorubicin
retention at these depths was correlated with an increase
in PgP expression, therefore changes in doxorubicin distri-
bution patterns throughout the spheroid tissue due to PgP
overexpression and inhibitors could not be assessed [32].
Multicellular spheroids allow good insight into drug fluo-
rescence however, they lack vasculature and certain micro-
environmental conditions that lead to specific
phenotypes such as multidrug resistance and tumor acid-
ity.
Here, we have investigated the effects of PgP overexpres-
sion and PgP inhibitors on doxorubicin distribution in
solid tumors grown in mice. The distribution of doxoru-
bicin is quite variable within tumor tissue. In well-vascu-
larized areas drug distribution is relatively uniform;
however in most areas of the tumor where there are few
blood vessels, distribution to cells distal from blood ves-
sels is limited so that many viable tumor cells have mini-
mal exposure to drug, allowing them to survive and
proliferate. For this reason, we selected areas of interest
within a tumor section that had low vascular density. We
examined doxorubicin distribution 10 minutes after intra-
venous administration because previous studies in our
laboratory have shown no difference in doxorubicin dis-
tribution in relation to the nearest blood vessel beyond
this time point [7].
Similar to data for MCCs, our results show an increase in
doxorubicin distribution in the PgP overexpressing
tumors AR1 and MCF-7/ADR compared to their wild-type
variants EMT6 and MCF-7, respectively. There is rapid cel-
lular uptake of doxorubicin in wild-type cells and this is
largely due to its ability to bind tightly to DNA [33], and
in tumors derived from them, large amounts of drug accu-
mulate in cells closest to blood vessels. Doxorubicin is a
PgP substrate, that is efficiently pumped out of tumor cells
where PgP is highly expressed [16]. Thus, in PgP overex-
pressing tumors there is less uptake and binding into
proximal cells, resulting in a shallower gradient of
decreasing doxorubicin fluorescence with increasing dis-
tance from tumor blood vessels. These results do not
imply that PgP overexpressing tumors allow for more
effective drug treatment, since cellular accumulation of
drug is essential for cytotoxicity, and PgP expression will
decrease relative uptake of substrate drugs in all tumor
cells. However, our results demonstrate that PgP efflux
can significantly alter the biodistribution of chemothera-
peutic agents, such that decreased proximal uptake of
drug may be counter-balanced by greater amounts of dox-
orubicin available to distal cells in solid tumors.
Methods of inhibiting PgP have been studied extensively
for over two decades. Many agents that modulate PgP
transport such as verapamil and cyclosporin were identi-
fied in the 1980s, and were evaluated as chemosensitizing
agents. These agents produced disappointing results in
clinical trials in part because their low binding affinities
necessitated the use of high doses, resulting in unaccepta-
ble toxicities [15]. In our studies, a relatively low dose of
verapamil (25 mg/kg) was used to determine its effect on
drug distribution. While toxicity is likely to be the primary
cause of the ineffectiveness of verapamil to improve the
sensitivity of tumors to substrate drugs, our studies show
that modification of doxorubicin distribution in tumors
might be an additional cause of their failure to improve
tumor response to chemotherapy.
Second generation PgP modulators include valspodar
(PSC 833), biricodar, and dexniguldipine. These agents
are more potent and specific than first generation inhibi-
Distribution of doxorubicin in solid tumors Figure 3
Distribution of doxorubicin in solid tumors. Murine 
AR1 tumors were treated with either doxorubicin (A) or 
PSC 833 and doxorubicin (C). Similarly, BC19 xenografts 
were treated with either doxorubicin (B) or PSC 833 and 
doxorubicin (D). Doxorubicin is shown in blue and blood 
vessels are shown in red. (Scale bars = 100 μm)
A  B
C D
Mouse 
Human BMC Cancer 2009, 9:356 http://www.biomedcentral.com/1471-2407/9/356
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tors [16]. Valspodar has been studied in clinical trials in
combination with cytotoxic agents [14,34]. A study by
Coley et al [35], that used fresh tumor material from
patients with soft-tissue sarcomas indicated that valspo-
dar at 1 nM had a modest effect to increase anthracycline
accumulation (by ~20%) in PgP positive samples. In a
study of women with epithelial ovarian cancer, the effect
was of a similar magnitude; these limited effects might
explain in part the disappointing results of clinical trials.
Some second generation PgP inhibitors are also, like cyto-
toxic agents, substrates of cytochrome P450 3A4, an
important enzyme involved in metabolism, and the com-
petition between cytotoxic drugs and PgP inhibitors for
cytochrome P450 activity has resulted in unpredictable
pharmacokinetic interactions. Here we found substantial
toxicity when a low dose of PSC 833 was combined with
doxorubicin. Marked pharmacologic interactions have
been observed in patients treated with this combination,
leading to substantial increases in hematologic toxicity
[34], and requiring use of lower doses of anticancer drugs
when used in combination.
Although cytotoxicity and pharmacokinetic interactions
explain partially why PgP inhibitors have not been very
effective in clinical trials, a clear explanation for the mini-
mal effects to increase mean cellular accumulation of drug
has yet to be provided. Studies to determine cellular accu-
mulation often involve homogenizing tumor tissue and
conducting high-performance liquid chromatography
(HPLC) [36,37]. This method is limiting, because it does
not give an indication of the distribution of drug.
Our study uses a non-orthotopic tumor mouse model to
show that tumor cells in areas far from blood vessels
The gradient of doxorubicin fluorescence intensity in relation to distance from the nearest blood vessel and a model of doxo- rubicin distribution in solid tumours Figure 4
The gradient of doxorubicin fluorescence intensity in relation to distance from the nearest blood vessel and a 
model of doxorubicin distribution in solid tumours. Mice-bearing AR1 tumors (A) or BC19 xenografts (B) were treated 
with either doxorubicin alone, or pretreated with verapamil or PSC 833 and doxorubicin. Tumors were resected, sectioned 
and imaged. Image analysis was undertaken using customized algorithms. Values represent mean ± standard error. In panel A, 
6, 10 and 9 tumors were analyzed, respectively. In panel B, 6, 7 and 6 tumors were analyzed, respectively. (C) represents a 
model of doxorubicin distribution without fluouresence interference from neighboring out-of-section blood vessels.BMC Cancer 2009, 9:356 http://www.biomedcentral.com/1471-2407/9/356
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where PgP inhibitors have no effect (or possibly even a
negative effect) due to changes in distribution of doxoru-
bicin, might counterbalance areas close to blood vessels
where uptake of doxorubicin into tumor cells is increased,
thus limiting the effectiveness of these inhibitors. While
tumor dynamics, vasculature and heterogeneity affect
drug distribution, this non-orthotopic mouse model is
still limited in fully representing the conditions in human
patients.
Computer- simulated mathematical models have shown
that adequate drug distribution is a crucial factor in deter-
mining drug effectiveness [38]. One model has demon-
strated that drug efflux from cells, enhanced by PgP, will
result in a longer diffusion length [39]. These mathemati-
cal models are powerful tools that can provide important
insights about drug distribution, because they can take
into account drug pharmacodynamics [40], the spatio-
temporal accumulation of drug [41], the link between
multiscale approaches [42,43], and the effects of local
drug, oxygen and nutrient gradients on tumor growth and
response [44]. Future studies integrating our data with
computer-simulated mathematical models may be a pow-
erful tool in determining drug distribution and its associ-
ation with drug effectiveness in human patients.
Conclusion
We have shown that PgP expression and inhibitors of PgP
function can influence doxorubicin distribution in some
solid tumors. The distribution of doxorubicin is more het-
erogeneous in wild-type tumors, than in those where con-
stituent cells express PgP: drug uptake is higher in cells
close to blood vessels in wild-type tumors, but there are
minimal differences in drug uptake by more distal cells.
Both the first-generation inhibitor verapamil and the sec-
ond-generation inhibitor valspodar alter drug penetration
in both a murine tumor and a human xenograft, leading
to improved uptake of doxorubicin only in tumor cells
within a restricted radius around functional blood vessels.
Whether PgP overexpressing tumors are treated with a PgP
inhibitor or not, cells distal to blood vessels at approxi-
mately 50-120 μm, show no significant difference in dox-
orubicin fluorescence (Table 1). Our modeling suggests
the possibility of a paradoxical effect of PgP inhibitors to
cause PgP overexpressing tumors to have increased uptake
of doxorubicin in proximal cells, minimal or no effect on
drug uptake at intermediate distances from blood vessels
but decreased drug uptake in more distal cells (Figure 4c).
These results emphasize that while limited cellular accu-
mulation of a drug is an important mechanism of drug
resistance, if there is a trade-off between uptake into prox-
imal cells and penetration to distal cells, therapeutic effec-
tiveness may be limited, especially for drugs like
doxorubicin that have a short half-life in the circulation.
Repopulation of tumor cells has been shown to occur in
regions far from blood vessels [29], and it is important to
consider factors that affect the distribution of chemother-
apeutic agents in solid tumors. Numerous clinical trials
evaluating the effects of verapamil or valspodar in combi-
nation with chemotherapeutic agents such as doxoru-
bicin, vincristine, dexamethasone, cyclophosphamide,
paclitaxel have shown that patients given concurrent
administration of PgP inhibitors with chemotherapeutic
agents have an increased toxicity and show modest or no
increase in survival [45-49]. These results provide insight
into an important limitation of PgP inhibitors and this
Tumor growth delay and toxicity studies Figure 5
Tumor growth delay and toxicity studies. Mice-bearing EMT6 tumors (A) or AR1 tumors (B) were treated with either 
saline, doxorubicin alone, verapamil alone, PSC 833 alone or pretreated with verapamil or PSC 833 in combination with doxo-
rubicin. Tumor volume and body weight was measured every 2-3 days. Values represent mean ± standard error (n = 5).BMC Cancer 2009, 9:356 http://www.biomedcentral.com/1471-2407/9/356
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principle is likely to be applicable to other membrane-
based drug efflux proteins such as multiple drug resistance
protein-1 (MRP-1) and suggest the importance of consid-
ering drug distribution in the design and development of
novel treatment strategies.
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